Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea

被引:10
|
作者
Lee, Young-Kyun [1 ]
Ahn, Soyeon [2 ]
Kim, Kyoung Min [3 ]
Suh, Chang Suk [4 ]
Koo, Kyung-Hoi [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Orthoped Surg, 82 Gumi Ro,173 Beon Gil, Seongnam 13620, South Korea
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Med Res Collaborating Ctr, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
[4] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seongnam, South Korea
关键词
Hip Fractures; Diphosphonate; Incidence; Korea; INTRAVENOUS BISPHOSPHONATE; ASYMPTOMATIC PATIENTS; FEMUR FRACTURES; SHAFT FRACTURES; THERAPY; RISK; BENEFITS; TRENDS;
D O I
10.3346/jkms.2018.33.e38
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of bisphosphonate. Methods: We conducted a hospital-based, retrospective cohort study in patients aged >= 45 years, who took bisphosphonate. The occurrence of AFF was estimated by using incidence rate, and the age-adjusted incidence rate to U.S. 2010 Census data. The association between occurrence of AFF and the duration of bisphosphonate use was examined. The cumulative probability of AFF was plotted per each duration of bisphosphonate use. Results: Among 10,338 individuals who took bisphosphonate, 13 patients with AFF following use of bisphosphonate were identified. The incidence rate was 85.9/100,000 person-years (95% confidence interval [CI], 50.2-146.9), and age-adjusted incidence rate was 72.7/100,000 person-years (95% CI, 29.1-175.8). In Poisson regression analysis, higher body mass index (BMI) was associated with an increased risk of AFF (relative risk, 1.2; 95% CI, 1.004-1.359). The cumulative probability of AFF increased abruptly when the duration of bisphosphonate use was 4 years or more. Conclusion: Among Korean patients, the incidence rate of AFF was on a par with those of western countries, and this can provide basic information to conduct further studies by evaluating risk and benefit of continuing bisphosphonate.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Atypical Femoral Fracture After the Withdrawal of Bisphosphonates
    Franekova, Lenka
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (04) : E675 - E676
  • [3] Atypical Femoral Fracture Risk in Patients Treated With Bisphosphonates
    Bauer, Douglas C.
    ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (12) : 936 - 937
  • [4] ASSESSMENT OF ATYPICAL FEMORAL FRACTURE RISK IN PATIENTS WITH LONG- TERM TREATMENT WITH BISPHOSPHONATES
    Cano, C.
    Rendon, D. A.
    Gonzalez, R.
    Borobio, G.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S263 - S263
  • [5] Bilateral atypical femoral fracture in osteoporotic patient treated with bisphosphonates
    Nam, Kiyeun
    Seo, Minsu
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [6] Long-term bisphosphonates use and atypical femoral fracture
    Bakhtiyarova, Gaukhar
    Tinazli, Mehtap
    Aydin, Deniz
    CUKUROVA MEDICAL JOURNAL, 2024, 49 (01): : 235 - 238
  • [7] Bilateral atypical femoral fracture in osteoporotic patient treated with bisphosphonates
    Seo, Minsu
    Nam, Kiyeun
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [8] ATYPICAL FEMORAL FRACTURE: THE PRICE FOR LONG TERM BISPHOSPHONATES ADHERENCE?
    Oprea, E. -T.
    Barbu, C. G.
    Fica, S. V.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S752 - S753
  • [9] Atypical bilateral femoral shaft fracture in patient treated with bisphosphonates
    Parrón Cambero R.
    Rey López A.
    Tomé-Bermejo F.
    Cibantos Martínez R.
    European Journal of Orthopaedic Surgery & Traumatology, 2013, 23 (Suppl 2) : S219 - S223
  • [10] ATYPICAL FEMORAL FRACTURES AFTER TREATMENT WITH BISPHOSPHONATES AND DENOSUMAB IN INFLAMMATORY AND SENILE OSTEOPOROSIS
    Melendez, L. Merino
    Llorente, I.
    Garcia, E.
    Garcia-Vicuna, R.
    Sanz, S. Castaneda
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 762 - 763